# US 2006/0233821 A1 · Compositions and methods for the inhibition of membrane fusion by paramyxoviruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0233821 A1
- Document ID: US20060233821A1
- Status: Published application
- Kind: A1
- Application number: 10/528,800
- Filed: 2002-11-13
- Published: 2006-10-19
- Earliest claimed: 2001-11-13
- Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Inventors: Christopher Broder; Katharine Bossart
- Web page: https://patentgrep.com/patent/US20060233821A1

## CPC

- A61K 38/162: {from virus}
- A61P 31/12: Antivirals
- C07K 14/005: from viruses
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2760/18222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18233: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Fusion of the membrane of enveloped viruses with the plasma membrane of a receptive host cell is a prerequisite for viral entry and infection and an essential step in the life cycle of all enveloped viruses, such as paramyxoviruses. The instant invention is directed to providing polypeptides which are a heptad portion of a Henipavirus F protein effective against fusion between a membrane of a paramyxovirus and a plasma membrane of a cell. The instant invention also provides nucleic acids, compositions, and methods effective against paramyxovirus infection. Accordingly, the instant invention provides therapeutic agents and vaccines effective against paramyxoviruses viruses, especially HeV or NiV.

## Claims

### Claim 1

An isolated polypeptide which is a heptad portion of a Henipavirus F protein that function to inhibit fusion of a membrane of a paramyxovirus and a plasma membrane of a cell.

### Claim 2 (depends on 1)

The polypeptide of claim 1 wherein said polypeptide comprises a biologically active fragment of a heptad portion of a Henipavirus F protein that functions to inhibit fusion of a membrane of a paramyxovirus and a plasma membrane of a cell.

### Claim 3 (depends on 1)

The polypeptide of claim 1 wherein said polypeptide comprises a deletion, substitutional, or insertional variant of a heptad portion of a Henipavirus F protein that functions to inhibit fusion of a membrane of a paramyxovirus and a plasma membrane of a cell.

### Claim 4 (depends on 1)

The polypeptide of claim 1 wherein said polypeptide is recombinant.

### Claim 5 (depends on 1)

The peptide of claim 1 wherein the polypeptide is derived from HeV or NiV.

### Claim 6

A polypeptide that comprises the polypeptide sequence of SEQ ID NO 1 or SEQ ID NO 2.

### Claim 7 (depends on 6)

The polypeptide of claim 6 wherein said polypeptide comprises a biologically active fragment of SEQ ID NO 1 or SEQ ID NO 2.

### Claim 8 (depends on 6)

The polypeptide of claim 6 wherein said polypeptide comprises a deletion, substitutional, or insertional variant of SEQ ID NO 1 or SEQ ID NO 2.

### Claim 9 (depends on 6)

The polypeptide of claim 6 wherein said polypeptide is recombinant.

### Claim 10 (depends on 6)

The peptide of claim 6 wherein the polypeptide is derived from HeV or NiV.

### Claim 11

A pharmaceutical composition comprising an effective amount of a polypeptide sequence of SEQ ID NO 1 or SEQ ID NO 2 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

The composition of claim 11 comprising a biologically active fragment of SEQ ID NO 1 or SEQ ID NO 2.

### Claim 13 (depends on 11)

The composition of claim 11 comprising a deletion, substitutional, or insertional variant of SEQ ID NO 1 or SEQ ID NO 2.

### Claim 14 (depends on 11)

The composition of claim 11 wherein the composition is a therapeutic or post-exposure prophylactic.

### Claim 15 (depends on 11)

The composition of claim 11 wherein the composition is a vaccine.

### Claim 16 (depends on 11)

A method for inhibiting fusion between a membrane of a paramyxovirus and a plasma membrane of a cell comprising administering a composition according to claim 11.

### Claim 17 (depends on 16)

The method of claim 16 wherein said paramyxovirus is of the genus Henipavirus.

### Claim 18 (depends on 16)

The method of claim 16 wherein said paramyxovirus is of the subfamily Paramyxovirina.

### Claim 19 (depends on 16)

The method of claim 16 wherein said paramyxovirus is HeB or NiV.

### Claim 20

An isolated polynucleotide sequence encoding a polypeptide that inhibits fusion between a membrane of a paramyxovirus and a plasma membrane of a cell, wherein said polynucleotide sequence is selected from the group consisting of:
a DNA sequence encoding a polypeptide of SEQ ID NO 1; and
a DNA sequence capable of hybridizing under high stringency conditions to the complement of a DNA sequence encoding a polypeptide of SEQ ID NO 1.

### Claim 21 (depends on 20)

A vector comprising a polynucleotide sequence of claim 20.

### Claim 22 (depends on 20)

A cell comprising a polynucleotide sequence of claim 20.

### Claim 23 (depends on 11)

A method for treating infection with a virus, comprising administering the composition of claim 11.

### Claim 24 (depends on 23)

The method of claim 23 wherein said virus is a paramyxovirus.

### Claim 25 (depends on 23)

The method of claim 23 wherein said paramyxovirus is of the genus Henipavirus.

### Claim 26 (depends on 23)

The method of claim 23 wherein said virus is HeV or NiV.

### Claim 27

An aptamer of a heptad portion of a Henipavirus F protein that functions to inhibit fusion of a membrane of a paramyxovirus and a plasma membrane of a cell.

### Claim 28

An aptamer of a polypeptide sequence of SEQ ID NO 1 or SEQ ID NO 2.

### Claim 29 (depends on 27)

The biologically active fragment of an aptamer of claim 27.

### Claim 30 (depends on 27)

A method for inhibiting fusion between a membrane of a paramyxovirus and a plasma membrane of a cell comprising administering an effective amount of an aptamer of claim 27.
